Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

hase II, randomized, double-blind, sham controlled trial of microplasmin intravitreal injection (125 μg) for the treatment of focal vitreomacular adhesion (separation of the vitreous from the retina) in patients with exudative (wet) AMD. The trial will enroll approximately 100 patients at up to 20 centers across five European countries. The primary endpoint of the trial is non-surgical resolution of vitreomacular adhesion, defined as the separation of the vitreous from the retina by 28 days. This will be assessed by the Central Reading Center based on optical coherence tomography (OCT) images. Additional measures of efficacy and safety will also be assessed over a one year follow-up period.

Microplasmin has the potential to transform the treatment of a number of other important back of the eye diseases as well as AMD. Microplasmin is currently being evaluated in a Phase III program of approximately 640 patients, for the non-surgical treatment of focal vitreomacular adhesion.

Dr. Patrik De Haes, CEO of ThromboGenics commenting on the announcement said, "We are very pleased to announce the start of a Phase II trial of microplasmin in such a significant condition as AMD. It is increasingly clear that vitreomacular adhesion plays a key role in AMD sufferers with a poorer prognosis. Microplasmin's potential to cleave the vitreous from the retina could therefore represent an important advance in the treatment of this patient group. The start of this trial underlines the potential broad applicability of our lead product, and is another important step as we create a profitable integrated company focused on cutting edge ophthalmic medicines."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III cl
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  Chuma Holdings, Inc. (OTCBB:CHUM) ... and turnkey support services for the lawfully organized ... processed and approved the Company,s name and symbol ... Corporation will be known as Chuma Holdings, Inc. ... through a merger with the Company,s wholly-owned subsidiary, ...
(Date:8/29/2014)... , Aug. 29, 2014 Pomerantz LLP ... S.A. ("EDAP" or the "Company") (NASDAQ: EDAP ) ... in United States District Court, Southern District of ... is on behalf of a class consisting of all ... 1, 2013 and July 30, 2014, inclusive (the "Class ...
(Date:8/29/2014)... Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September ... and Chief Executive Officer, will provide an update on ... (9:55 a.m., Pacific Daylight Time).   A ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
(Date:8/30/2014)... Recently, Skmen.com, a well-known clothing manufacturer, has announced its ... the middle of September, all the company’s new and ... to 30 percent off. , As a matter ... carefully made and come with quality guarantees. They can ... is popular for its fashionable, high quality clothes for ...
(Date:8/30/2014)... August 30, 2014 Hands ... Spa-on-Wheels which offers the complete spa experience combining ... lighting and the most important ingredient of all, ... dedicated licensed pro's! People will enjoy the get-away ... Kaplan-Pelle. The website reads, "Step into the spacious, ...
(Date:8/30/2014)... 2014 Daily Gossip reveals in its recently ... a method created by Sarah Summer, who can perfectly understand ... of this new program actually had to deal with this ... be able to access it, in an all-natural holistic cure ... finding an effective cure for yeast infection. The author of ...
(Date:8/30/2014)... Ticket Down is a ... tickets in NYC. This popular ticket exchange ... all day session, evening session, courtside seats, grandstand seats, ... prestigious Grand Slam Tournament. , The 2014 U.S. Open ... Open Tennis Championship: Men's/Women's 3rd Round - Session 11 ...
(Date:8/30/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Cell Disruptor including its ... explores global and China’s top manufacturers of Cell ... and market share etc. The report further analyzes ...
Breaking Medicine News(10 mins):Health News:Huge Deals On 2014 Long Casual Dresses Unveiled By Skmen.com 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4
... junior doctors' has been reduced in order to increase their ... medics found that cutting down working hours alone is not ... of rotas was essential. ,The Occupational and Environmental ... Auckland universities in New Zealand. ,In the UK, ...
... system of medicine into English is on the verge of completion. ... in palm leaf manuscripts, would be published soon, according to ... Tamil Nadu. ,As many as six Sidha ... government for two years and produced six volumes, the minister revealed ...
... that turmeric, a widely used ingredient in the Indian ... prostate cancer. ,ASC-J9, a synthetic chemical ... name for turmeric, shows considerable promise against prostate cancer, ... a debilitating neurodegenerative condition, researchers at the University ...
... than the hottest month in the last 100 years. There ... microorganism cryptosporidium, in this part of the continent. ,The ... just 52 , for the same period last year. ... just 'the tip of the iceberg'. ,'We ...
... National Institute of Neurological Disorders and Stroke (NINDS) today ... the nutritional supplement creatine// can slow the progression of ... therapy for PD or any other condition, it is ... of creatine for PD was identified by Parkinson’s researchers ...
... Clinical Nursing found that 33% of women in UK experience painful ... who had some kind of sex related problems after child birth. ... prominent in Asian women, older women and in women who had ... of women who had a Caesarean, 34% who had a normal ...
Cached Medicine News:Health News:Rest for Doctors to Ensure Patients’ Safet 2Health News:NIH Announces Phase III Clinical Trial of Creatine for Parkinson's Disease 2Health News:NIH Announces Phase III Clinical Trial of Creatine for Parkinson's Disease 3
... bed is especially designed to make your bariatric ... caregivers who manage them. , ,When caring ... pulling up in bed, turning, sitting, standing ... for patients. Excel Care ES bed offers features ...
... Caregiver safety. Patient dignity. A single ... Bariatric Bed to provide added safety where ... is engineered to help protect the caregiver ... efficiency. The bed functions just like other ...
... We offer a wide selection of solutions ... therapy use. The sterile water for inhalation ... in plastic pour bottles in 500 and ... prefilled nebulizer kits or can be used ...
... Nebulizer Disposable Prefilled 28%-100% FIO 2 ... prefilled nebulizers provide unmatched performance and ease of ... aerosols adjustable from 28% to 100% FIO 2 ... sterile water for inhalation, USP; 0.45% sodium chloride ...
Medicine Products: